Anavex Encouraged by Data Showing Sigma-1 Receptor Reduces Tau Dysfunction, a Hallmark of Alzheimer’s Disease

New Report Validates Therapeutic Application of Anavex Compounds in Tau Diseases NEW YORK, NY – May 21, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, is encouraged by…

Anavex Releases Promising Full Preclinical Epilepsy Data at Antiepileptic Drug Trials XIII Conference

Company’s lead Sigma-1 agonist, ANAVEX 2-73 demonstrates robust anti-seizure effects in well established preclinical seizure models NEW YORK, NY – May 18, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types…